


Appl. No. 10/524,693
Amendment dated: February 21, 2008
Reply to OA of: November 21, 2007

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1(currently amended). A pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione of Formula I:



wherein:

R₁ represents methoxy, ethoxy or hydroxy;

R₂ represents methoxy, ethoxy, hydroxy or hydrogen; and

n represents 2 or 3,

or a pharmacologically acceptable ~~solvate~~ hydrate thereof.

2(original). A pamoate salt as claimed in Claim 1, wherein R₁ represents methoxy and R₂ represents methoxy or hydrogen.

3(original). A pamoate salt as claimed in Claim 2, wherein the pamoate salt is 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

4(original). A pamoate salt as claimed in Claim 2, wherein the pamoate salt is 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione


Appl. No. 10/524,693
Amendment dated: February 21, 2008
Reply to OA of: November 21, 2007

pamoate.

5(previously presented). A pamoate salt as claimed in Claim 1, wherein the pamoate salt is in the form of its (-) isomer.

6(canceled).

7(currently amended). A pharmaceutical composition comprising a therapeutically effective amount of a pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione of Formula I:



wherein:

R₁ represents methoxy, ethoxy or hydroxy;

R₂ represents methoxy, ethoxy, hydroxy or hydrogen; and

n represents 2 or 3,

or a pharmacologically acceptable ~~solvate~~ hydrate thereof

and a pharmacologically acceptable diluent or carrier.

8(original). A pharmaceutical composition as claimed in Claim 7 for the treatment or prophylaxis of a stress-related affective disorder.


9(previously presented). A pharmaceutical composition as claimed in Claim 7, wherein the 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione has the Formula (I) wherein R_1 represents methoxy and R_2 represents methoxy or hydrogen and/or wherein the pamoate salt is in the form of its (-) isomer and/or wherein the pamoate salt is in the form of its hydrate.

10(original). A pharmaceutical composition as claimed in Claim 9, wherein the pamoate salt is 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

11(original). A pharmaceutical composition as claimed in Claim 9, wherein the pamoate salt is 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

Claims 12-24(canceled).

25(currently amended). A method for the treatment or prophylaxis of a stress-related affective disorder which comprises administering to a human or animal patient a therapeutically effective or prophylaxis effective ~~an effective~~ amount of a pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione of Formula I:



wherein:

Appl. No. 10/524,693
Amendment dated: February 21, 2008
Reply to OA of: November 21, 2007

R₁ represents methoxy, ethoxy or hydroxy;
R₂ represents methoxy, ethoxy, hydroxy or hydrogen; and
n represents 2 or 3,
or a pharmacologically acceptable ~~solvate~~ hydrate thereof.

26(original). A method as claimed in Claim 25, wherein the stress-related affective disorder is selected from the group consisting of agoraphobia; anorexia nervosa; anxiety; anxiogenesis associated with withdrawal from drugs of abuse; bulimia nervosa; chronic paroxysmal hemicrania; depression (including prevention of depressive recurrences); diminution of the immune response associated with anxiety, depression or bereavement; disorders of sleep initiation or maintenance; disorders of the sleep-awake schedule; dream anxiety attacks; Huntington's chorea; Kleine-Levin syndrome; memory disturbance; Ménière's disease, menstrual-associated sleep syndrome; migraine; motion sickness; nausea incompletely relieved by 5HT₃ antagonist administration, neurogenic pain; neuropathic pain; obsessive-compulsive disorder; panic attacks; posttraumatic stress disorder; pre-menstrual dysphoric disorder; recurrent brief depression; Restless Leg syndrome, schizophrenia; senile dementia; serotonin-irritation syndrome; sleep apnoea; sleep related cardiovascular symptoms; sleep related epileptic seizures; sleep-related cluster headaches; sleep-related myoclonus syndrome; social phobia; sudden infant death syndrome; and tinnitus.

27(original). A method as claimed in Claim 26, wherein the stress-related affective disorder is anxiety.

28(original). A method as claimed in Claim 26, wherein the stress-related affective disorder is depression.

29(original). A method as claimed in Claim 26, wherein the stress-related affective disorder is migraine.

Appl. No. 10/524,693
Amendment dated: February 21, 2008
Reply to OA of: November 21, 2007

30(original). A method as claimed in Claim 26, wherein the stress-related affective disorder is sleep apnoea.

31(previously presented). A method as claimed in Claims 25, wherein R_1 represents methoxy and R_2 represents methoxy or hydrogen and/or wherein the pamoate salt is in the form of its (-) isomer and/or wherein the pamoate salt is in the form of its hydrate.

32(original). A method as claimed in Claim 31, wherein the pamoate salt is 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.

33(original). A method as claimed in Claim 31, wherein the pamoate salt is 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.